Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II S-1 plus levofolinate as first-line therapy for metastatic colorectal cancer
jRCT2080220727Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and levoleucovorin in metastatic colon cancer (mCRC), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
tegafurlevoleucovorin
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080220727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220727.